Terbinafine for Dermatophyte Infections and Onychomycosis
Primary Recommendation
Oral terbinafine 250 mg daily is the first-line treatment for dermatophyte onychomycosis: 6 weeks for fingernails and 12-16 weeks for toenails, with superior efficacy and tolerability compared to all alternatives. 1
Dosing Regimens
Standard Oral Therapy (First-Line)
- Fingernail onychomycosis: 250 mg once daily for 6 weeks 1, 2
- Toenail onychomycosis: 250 mg once daily for 12-16 weeks 1, 2
- Pediatric dosing (unlicensed but recommended):
Alternative Pulse Therapy
While continuous therapy remains standard, pulse regimens have been studied with variable results:
- Monthly pulse: 500 mg daily for 7 days per month for 4 months showed comparable efficacy to continuous therapy 3
- Quarterly pulse: 500 mg daily for 7 days every 3 months (4 total pulses) demonstrated similar effectiveness with potentially fewer side effects 3
- Three-pulse regimen: 500 mg daily for 7 days, repeated twice at 3-week intervals, achieved 74.5% complete cure when combined with topical terbinafine 4
However, pulse therapy remains less established than continuous therapy and should be reserved for specific situations where continuous dosing is problematic. 3, 4
Topical Therapy
- Tinea pedis, corporis/cruris, cutaneous candidiasis: 1% cream applied once or twice daily for 1-2 weeks achieves >80% mycological cure 5
- Topical formulations are first-line for limited superficial infections but inadequate for onychomycosis as monotherapy 5
Efficacy Data
Superiority Over Alternatives
Terbinafine demonstrates clear superiority over itraconazole for dermatophyte onychomycosis, the only other reasonable first-line option:
- Complete cure at 72 weeks: 55% with terbinafine (16 weeks) vs. 26% with pulsed itraconazole 1
- Mycological cure: 76-81% with terbinafine vs. 38-49% with itraconazole 6
- 5-year follow-up data: Mycological cure maintained in 46% with terbinafine vs. 13% with itraconazole 1
- Relapse rates: 21-23% with terbinafine vs. 48-53% with itraconazole 1, 6
Terbinafine also outperforms griseofulvin and fluconazole for dermatophyte infections 1, 5, 6
Expected Timeline
- Re-evaluation: 3-6 months after treatment initiation 1
- Optimal clinical effect: Several months after treatment completion due to nail growth time 2
- Nail persistence: Terbinafine remains detectable in nails for at least 30 weeks post-treatment 6
Safety Monitoring and Contraindications
Mandatory Baseline Testing
Obtain baseline liver function tests (ALT, AST) and complete blood count before initiating therapy 1, 2:
- Required for all patients with history of heavy alcohol use, hepatitis, or hematological abnormalities 1
- Strongly recommended for all pediatric patients (unlicensed use) 1
- Consider for all patients given rare but serious hepatotoxicity risk 2
Absolute Contraindications
- Active or chronic liver disease 1
- History of allergic reaction to oral terbinafine (risk of anaphylaxis) 2
Relative Contraindications/Cautions
- Renal impairment 1
- Hepatic impairment 1
- Immunocompromised status 2
- Lupus erythematosus (can aggravate or cause lupus-like syndrome) 1, 2
- Psoriasis (can aggravate) 1
Critical Adverse Effects Requiring Immediate Discontinuation
Hepatotoxicity (Most Serious)
Discontinue immediately if patients develop: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 2
- Incidence of serious adverse events: 0.04% 1
- Rare reports of liver failure requiring transplant or resulting in death 2
- Usually occurs in patients with pre-existing liver disease 1
Severe Cutaneous Reactions
Discontinue immediately if: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, or DRESS syndrome develop 1, 2
- Symptoms include: hives, mouth sores, blistering/peeling skin, facial/throat swelling, difficulty swallowing or breathing 2
Sensory Disturbances (Potentially Permanent)
Discontinue if taste or smell disturbance occurs 1, 2:
- Taste disturbance: Can be severe, prolonged, or permanent 1, 2
- Smell disturbance: Including complete loss of smell, may be prolonged or permanent 2
- Patients must be warned of permanence risk before starting therapy 1
Hematologic Toxicity
Discontinue if neutrophil count ≤1,000 cells/mm³ 2
- Severe neutropenia has been reported 2
Psychiatric Effects
Monitor for and discontinue if depressive symptoms develop 2
- Depressive symptoms have been reported with terbinafine use 2
Common Adverse Effects (Generally Manageable)
Most common side effects (>2% incidence) 2:
- Gastrointestinal (49%): nausea, diarrhea, dyspepsia, abdominal pain, flatulence 1, 2
- Dermatological (23%): rash, pruritus, urticaria, eczema 1, 2
- Headache 1, 2
- Liver enzyme abnormalities (usually mild) 2
Drug Interactions
Terbinafine has minimal drug-drug interactions compared to azole antifungals, a significant advantage 1, 5:
- Primary interaction: Inhibits CYP450 2D6 isoenzyme 1, 2
- Affected drugs: Desipramine, certain beta-blockers, antiarrhythmics, SSRIs metabolized by 2D6 2
- Other interactions: Cimetidine, fluconazole, cyclosporine, rifampin, caffeine 2
This low interaction profile makes terbinafine preferable to itraconazole in patients on multiple medications 5, 6
Special Populations
Pregnancy and Lactation
- Pregnancy: Not recommended; should not start during pregnancy without discussion 2
- Breastfeeding: Terbinafine passes into breast milk and may harm infant; discuss alternatives 2
Photosensitivity
Advise patients to minimize exposure to natural and artificial sunlight (including tanning beds, UVA/B treatment) while on therapy 2
Emerging Resistance Concerns
Terbinafine Resistance
Resistance to terbinafine is increasing globally, particularly with Trichophyton mentagrophytes and T. indotineae, with origins traced to South Asia 7, 8, 9:
- SQLE gene mutations (F397L, L393F, A448T) strongly associated with clinical resistance 7, 9
- Provisional MIC threshold for resistance: 1.69 μg/mL 7
- T. indotineae: Most prevalent resistant isolate with MICs up to 8 μg/mL for terbinafine 9
When to Suspect Resistance
- Treatment failure after appropriate duration and dosing 7, 8
- Recent travel to or from South Asia 9
- Recalcitrant infections despite compliance 8
Management of Resistant Cases
If terbinafine resistance is suspected or confirmed:
- Second-line: Itraconazole 200 mg daily for 12 weeks continuous, or 400 mg daily for 1 week/month (2 pulses for fingernails, 3 for toenails) 1, 9
- Third-line alternatives (off-label): Voriconazole or posaconazole for difficult-to-treat cases that have failed terbinafine, itraconazole, and fluconazole 8, 9
- Consider SQLE mutation testing where available to guide therapy selection 7, 9
Do not use newer generation azoles (voriconazole, posaconazole) unless traditional agents have been thoroughly evaluated first 8
Clinical Pearls and Pitfalls
Common Pitfalls to Avoid
- Inadequate treatment duration: Full 12-16 weeks required for toenails despite early improvement 1, 2
- Failure to warn about permanent taste/smell loss: This must be discussed before starting therapy 1, 2
- Missing baseline liver function tests: Required for safe monitoring 1, 2
- Expecting immediate cure: Clinical improvement continues for months after treatment cessation 2, 6
Optimizing Outcomes
- Re-evaluate at 3-6 months: Give additional treatment if disease persists 1
- Combination therapy: Consider adding topical amorolfine or ciclopirox for severe cases 1
- Patient education: Emphasize adherence and warning signs requiring immediate discontinuation 2
Higher Dosing Considerations
Recent evidence suggests 500 mg daily may be more effective than standard 250 mg dosing for onychomycosis 10, though this remains off-label. However, for tinea corporis/cruris, 500 mg showed no additional benefit over 250 mg 11. Standard dosing remains recommended until further evidence emerges.